Efficacy of prolotherapy in temporomandibular joint disorders with hypertonic dextrose and Polydeoxyribonucleotide (PDRN).

Other predictors, including sex ( p = 0.868), TMD subtypes (only osteoarthritis without soft tissue problems or other TMDs with soft tissue problems, p = 0.230; only soft tissue problems or soft tissue problems with osteoarthritis, p = 0.124; TMD symptoms with or without masticatory muscle problems, p = 0.353), baseline joint sound ( p = 0.627), and baseline deviation or deflection during mouth opening ( p = 0.198), did not reach statistical significance. 3.1 Comparison of treatment outcomes between PDRN and hypertonic dextrose solution in TMJ prolotherapy In comparison with prolotherapy agents between PDRN and hypertonic dextrose solution, the baseline characteristics, including age, sex, TMD side, and baseline MMO and VAS, showed no significant differences between the two groups ( Table 2 ).

also in 111,027 other papers